Venetoclax (ABT-199)

製品コードS8048 バッチS804819

印刷

化学情報

Chemical Structure Synonyms GDC-0199 Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C45H50ClN7O7S
分子量 868.44 CAS No. 1257044-40-8
Solubility (25°C)* 体外 DMSO 100 mg/mL (115.14 mM)
Water Insoluble
Ethanol Insoluble
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.
in vitro Venetoclax (ABT-199) shows less sensitivity to Bcl-xL, Mcl-1 and Bcl-w with Ki of 48 nM, > 444 nM and 245 nM, respectively. It potently inhibits FL5.12-Bcl-2 cells, RS4;11 cells with EC50 of 4 nM and 8 nM, while shows low activity against FL5.12-Bcl-xL cells with EC50 of 261 nM. This compound induces a rapid apoptosis in RS4;11 cells with cytochrome c release, caspase activation, the externalization of phosphatidylserine and the accumulation of sub-G0/G1 DNA. Quantitative immunoblotting reveals that sensitivity to it correlated strongly with the expression of Bcl-2, including NHL, DLBCL, MCL, AML and ALL cell lines. It also induces apoptosis in CLL with an average EC50 of 3.0 nM. [1]
in vivo Venetoclax (ABT-199) causes a maximal tumor growth inhibition of 95% and tumor growth delay of 152% in RS4;11 xenografts. It also inhibits xenograft growth (DoHH2, Granta-519) as a single agent or in combination with SDX-105 and other agents. [1]
特徴 Re-engineered version of ABT-263 (Navitoclax).

プロトコル(参考用のみ)

キナーゼアッセイ Binding affinity assays
Binding affinities (Ki or IC50) of Venetoclax (ABT-199) against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Its binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and this compound at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
細胞アッセイ 細胞株 NHL, DLBCL, MCL, AML and ALL cell lines
濃度 ~1 μM
反応時間 48 hours
実験の流れ Venetoclax (ABT-199) is diluted in half-log steps starting at 1 μM-0.05 nM and used to treat RS4;11 cells seeded at 5 × 104 per well in 96-well plates. Leukemia and lymphoma cell lines are seeded at 1.5-2 × 104 cells per well in the appropriate medium and incubated with this compound for 48 h. Effects on proliferation are determined using Cell TiterGlo reagent. EC50 values are determined by nonlinear regression analysis of the concentration-response data.
動物実験 動物モデル Female C.B-17 SCID mice (DoHH2 and Granta-519 xenografts) and female C.B-17 SCID-beige mice (RS4;11 and Toledo xenografts)
投薬量 ~100 mg/kg
投与方法 Orally

参考

  • https://pubmed.ncbi.nlm.nih.gov/23291630/

カスタマーフィードバック

Data from [Data independently produced by Mol Oncol, 2014, 10.1016/j.molonc.2014.09.008]

Data from [J Biol Chem, 2014, 289(23), 16190-9]

Data from [Data independently produced by , , Blood, 2015, 126(11):1346-56]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo [ Cell, 2025, S0092-8674(25)00689-0] PubMed: 40645177
Anti-BCL2 therapy eliminates giant congenital melanocytic nevus by senolytic and immune induction [ Signal Transduct Target Ther, 2025, 10(1):161] PubMed: 40374605
High mtDNA content identifies oxidative phosphorylation-driven acute myeloid leukemias and represents a therapeutic vulnerability [ Signal Transduct Target Ther, 2025, 10(1):222] PubMed: 40653487
Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors [ Mol Cancer, 2025, 24(1):154] PubMed: 40442785
PIM2 inhibition promotes MCL1 dependency in plasma cells involving integrated stress response-driven NOXA expression [ Nat Commun, 2025, 16(1):256] PubMed: 39747141
CREBBP inactivation sensitizes B cell acute lymphoblastic leukemia to ferroptotic cell death upon BCL2 inhibition [ Nat Commun, 2025, 16(1):4274] PubMed: 40393984
Oncogenic role of RARG rearrangements in acute myeloid leukemia resembling acute promyelocytic leukemia [ Nat Commun, 2025, 16(1):617] PubMed: 39805831
Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy [ Microbiome, 2025, 13(1):56] PubMed: 40022244
A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities [ Cell Rep Med, 2025, S2666-3791(25)00102-8] PubMed: 40147445
Development of a robust BH3 drug toolkit for precision medicine in hematologic malignancies [ Theranostics, 2025, 15(12):5705-5718] PubMed: 40365276

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。